Literature DB >> 20504406

Neurotensin modulates dopamine neurotransmission at several levels along brain dopaminergic pathways.

P Kitabgi1.   

Abstract

Neurotensin is a tridecapeptide that was isolated 15 years ago from bovine hypothalamus and, since then, has been shown to fulfill the major criteria that define a neurotransmitter/neuromodulator. There is considerable evidence that neurotensin interacts with mesencephalic dopamine systems. Anatomical and functional data indicate that neurotensin modulates dopamine neurotransmission at all levels along nigrostriatal and mesolimbic dopamine pathways. The peptide appears to functionally antagonize the effects that the amine exerts via both presynaptic (auto) and postsynaptic dopamine receptors. This confers a neuroleptic-like pharmacological profile to neurotensin. In addition, extensive neurotensin/dopamine colocalization occurs in a subpopulation of mesencephalic dopamine neurons that project to the prefrontal cortex. Recently, the neurotensin precursor has been shown to contain another neurotensin-like peptide, neuromedin N, that binds with high affinity to brain neurotensin receptors and displays some neuroleptic-like effects. Therefore, neuromedin N may be considered as a potential comodulator (with neurotensin) of dopamine functions. Given the implications of dopamine systems in certain neuropathological and psychotic disorders such as Parkinson's disease and schizophrenia it is likely, as already suggested by some experimental evidence, that neurotensin plays an important role in the etiology and pathogenesis of these diseases.

Entities:  

Year:  1989        PMID: 20504406     DOI: 10.1016/0197-0186(89)90110-1

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  7 in total

1.  Central neurotensin receptor activation produces differential behavioral responses in Fischer and Lewis rats.

Authors:  Pat Bauco; Pierre-Paul Rompré
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

2.  Characterization and distribution of binding sites for a new neurotensin receptor antagonist ligand, [3H]SR 48692, in the guinea pig brain.

Authors:  C Betancur; M Canton; D Gully; G Vela; D Pélaprat; W Rostène
Journal:  J Pharmacol Exp Ther       Date:  1995-06       Impact factor: 4.030

3.  Rational design of novel neurotensin mimetics: discovery of a pharmacologically unprecedented agent exhibiting concentration-dependent dual effects as antagonist and full agonist.

Authors:  Y P Pang; J Zaidi; A P Kozikowski; B Cusack; E Richelson
Journal:  J Comput Aided Mol Des       Date:  1994-08       Impact factor: 3.686

Review 4.  Neurotensin receptors: binding properties, transduction pathways, and structure.

Authors:  J P Vincent
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

5.  Presence of somatostatin or neurotensin in lateral septal dopaminergic axon terminals of distinct hypothalamic and midbrain origins: convergence on the somatospiny neurons.

Authors:  R L Jakab; C Leranth
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

6.  Neurochemical heterogeneity of the primate nucleus accumbens.

Authors:  K Ikemoto; K Satoh; T Maeda; H C Fibiger
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

7.  Turning behavior induced by intrastriatal injection of neurotensin in mice: sensitivity to non-peptide neurotensin antagonists.

Authors:  M Poncelet; C Gueudet; D Gully; P Soubrié; G Le Fur
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.